Skip to content
stoqly

Alnylam Pharmaceuticals, Inc.

ALNY Nasdaq Pharmaceutical Preparations Financials FY2016–FY2025

Revenue Total sales reported in the income statement.
$3.7B
65.2% vs prior year
Operating margin Operating income as a share of revenue.
13.5%
21.4 pts
Net income Profit after all expenses, interest and tax.
$314M
Free cash flow Cash from operations minus capital spending.
$465M
Return on capital After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap Last close times the latest diluted share count, so it is approximate.
—
P/E Last close divided by diluted earnings per share over the last four quarters.
—
On $2.33 EPS (TTM)

What Alnylam Pharmaceuticals, Inc. does

No business description yet.

Legal name
ALNYLAM PHARMACEUTICALS, INC.
Fiscal year ends
December 31, 2025
Latest annual report
10-K · Feb 12, 2026
Accession · CIK
0001628280-26-007497
0001178670

Revenue and margins

Alnylam Pharmaceuticals, Inc. had $3.7B of revenue in fiscal 2025, up 65.2% on the year before.

Revenue
Revenue
Margins, % of revenue
Gross Operating Net FCF
Margins, % of revenue
Gross Operating Net FCF

Net income and earnings per share

Loss periods are shown in red.

Net income
Net income
Diluted EPS
Diluted EPS

Returns on capital

After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.

Return on capital, equity and assets (annual)
Return on capital Return on equity Return on assets

Cash flow

Free cash flow was $465M in fiscal 2025, 12.5% of revenue. Cash from operations minus capital spending.

Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations Capital spending
Cash from operations vs capital spending
Cash from operations Capital spending

Dividends, buybacks and share count

Alnylam Pharmaceuticals, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 5.5%.

Dividends and buybacks
Dividends Buybacks
Diluted shares outstanding (annual)

Balance sheet

Cash, debt and the ratios that show how comfortably Alnylam Pharmaceuticals, Inc. can carry it.

Cash vs debt (incl. leases)
Cash Debt
Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments $2.4B$2.2B$2.4B$2.7B$2.9B
Debt incl. finance leases $676M————
Debt / equity 1.1x————
Interest coverage −5.0x−5.0x−2.3x−1.2x2.0x
Current ratio 4.0x3.5x3.1x2.8x2.8x
Quick ratio 3.9x3.3x3.0x2.7x2.7x
Total assets $3.6B$3.5B$3.8B$4.2B$5.0B
Total liabilities $3.1B$3.7B$4.1B$4.2B$4.2B
Shareholders' equity $588M−$158M−$221M$67.1M$789M
Net debt (− = net cash) −$1.7B————

Insider trades

Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.

Bought, 12 months

$0.0M

0 insiders

Sold, 12 months

$0.0M

0 insiders

Of sales under plans

—

$0.0M

No open-market insider trades in the last 12 months.

Piotroski F-score

Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.

TestFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net income is positive ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✓
Cash from operations is positive ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✓ ✕ ✓
Return on assets rose — ✓ ✕ ✓ ✓ ✓ ✕ ✓ ✓ ✓
Cash from operations exceeds net income ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
Debt fell relative to assets — — — — — ✕ — — — —
Current ratio rose — ✓ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕
Share count didn't rise — ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕ ✕
Gross margin rose — — ✕ ✕ ✕ ✓ ✓ ✕ ✓ ✕
Revenue rose relative to assets — ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓
F-score — / 34 / 72 / 83 / 83 / 84 / 93 / 84 / 84 / 85 / 8
Accruals ratio −8.1%−6.6%−11.1%−30.6%−8.4%−6.0%−16.4%−14.8%−6.7%−4.6%
Altman Z'' −0.918.26−0.09−2.40−1.67−2.17−4.01−3.07−2.60−0.11

10 years of figures

US$ millions unless stated. Hover a ratio's name for its definition.

Download CSV
Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue $47.2M $89.9M $74.9M $220M $493M $844M $1.0B $1.8B $2.2B $3.7B
Gross profit — $89.9M $73.1M $195M $419M $729M $897M $1.6B $1.9B $3.0B
Research and development $382M $391M $505M $655M $655M $792M $883M $1.0B $1.1B $1.3B
Operating income −$425M −$500M −$815M −$939M −$828M −$709M −$785M −$282M −$177M $502M
Interest expense — — $0.0M $0.0M $84.5M $143M $156M $121M $142M $253M
Pretax income −$410M −$491M −$761M −$885M −$856M −$852M −$1.1B −$434M −$377M $323M
Income tax $0.0M $0.0M $0.8M $0.9M $2.7M $0.7M $4.2M $6.7M −$99.2M $9.4M
Net income −$410M −$491M −$761M −$886M −$858M −$853M −$1.1B −$440M −$278M $314M
Diluted EPS −$4.79 −$5.42 −$7.57 −$8.11 −$7.46 −$7.20 −$9.30 −$3.52 −$2.18 $2.33
Diluted shares 0.09B 0.09B 0.10B 0.11B 0.11B 0.12B 0.12B 0.12B 0.13B 0.13B
Cash flow
Cash from operations −$308M −$383M −$563M −$278M −$615M −$642M −$541M $104M −$8.3M $524M
Capital expenditure $64.6M $104M $127M $140M $70.4M $76.4M $72.1M $62.2M $34.3M $58.7M
Free cash flow −$372M −$487M −$690M −$419M −$685M −$718M −$613M $41.9M −$42.6M $465M
Depreciation and amortization $15.1M $13.4M $15.2M $17.2M $34.8M $47.6M $44.5M $54.1M $56.7M $55.7M
Stock-based compensation $75.5M $92.8M $158M $175M $140M $166M $231M $222M $272M $348M
Balance sheet
Cash and short-term investments $618M $1.7B $1.1B $1.5B $1.8B $2.4B $2.2B $2.4B $2.7B $2.9B
Total debt — — — — $191M $676M — — — —
Current assets $672M $1.8B $1.2B $1.7B $2.6B $2.8B $2.7B $3.0B $3.3B $4.1B
Current liabilities $132M $144M $179M $353M $585M $696M $768M $968M $1.2B $1.5B
Inventory — — $24.1M $56.3M $75.2M $86.4M $129M $89.1M $78.5M $82.7M
Property and equipment, net $115M $182M $321M $425M $465M $502M $523M $526M $503M $513M
Total assets $1.3B $2.0B $1.6B $2.4B $3.4B $3.6B $3.5B $3.8B $4.2B $5.0B
Total liabilities $343M $228M $273M $956M $2.4B $3.1B $3.7B $4.1B $4.2B $4.2B
Preferred stock — — $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M $0.0M
Shareholders' equity $920M $1.8B $1.3B $1.4B $1.0B $588M −$158M −$221M $67.1M $789M
Margins
Gross margin — 100.0% 97.6% 88.6% 84.9% 86.4% 86.5% 85.3% 86.4% 81.8%
Operating margin −900.3% −556.2% −1,087.6% −427.5% −168.1% −83.9% −75.7% −15.4% −7.9% 13.5%
EBITDA margin −868.2% −541.3% −1,067.2% −419.7% −161.0% −78.3% −71.4% −12.5% −5.3% 15.0%
Net margin −869.6% −545.9% −1,016.6% −403.2% −174.1% −101.0% −109.0% −24.1% −12.4% 8.4%
FCF margin −789.4% −541.6% −920.5% −190.5% −139.1% −85.0% −59.1% 2.3% −1.9% 12.5%
Returns
Return on capital employed −37.5% −27.0% −58.4% −46.0% −29.4% −24.0% −28.3% −9.9% −5.8% 14.3%
Return on equity −44.6% −36.5% −49.6% −64.7% −69.9% −106.3% −526.1% — — 73.3%
Return on assets −32.5% −30.1% −42.7% −44.6% −29.6% −24.2% −31.5% −11.9% −6.9% 6.8%
Return on tangible equity −44.6% −27.8% −58.5% −61.6% −84.5% −145.0% — — −414.6% 39.8%
Growth
Revenue growth — 90.7% −16.7% 193.4% 124.3% 71.3% 22.9% 76.2% 23.0% 65.2%
FCF growth — — — — — — — — −201.5% —
Share count change — 5.8% 11.1% 8.6% 5.2% 3.0% 2.7% 2.6% 2.2% 5.5%
Financial health
Debt / equity — — — — 0.2x 1.1x — — — —
Interest coverage — — — — −9.8x −5.0x −5.0x −2.3x −1.2x 2.0x
Current ratio 5.1x 12.2x 6.7x 4.9x 4.5x 4.0x 3.5x 3.1x 2.8x 2.8x
Quick ratio 5.1x 12.2x 6.6x 4.7x 4.3x 3.9x 3.3x 3.0x 2.7x 2.7x
Capital allocation
Capex / revenue 136.9% 115.9% 169.4% 63.8% 14.3% 9.0% 6.9% 3.4% 1.5% 1.6%
Stock comp / revenue 160.2% 103.2% 210.6% 79.6% 28.4% 19.6% 22.2% 12.1% 12.1% 9.4%
Quality scores
Piotroski F-score — 4.0 2.0 3.0 3.0 4.0 3.0 4.0 4.0 5.0
Altman Z'' −0.9 8.3 −0.1 −2.4 −1.7 −2.2 −4.0 −3.1 −2.6 −0.1
Accruals ratio −8.1% −6.6% −11.1% −30.6% −8.4% −6.0% −16.4% −14.8% −6.7% −4.6%

Source: SEC EDGAR XBRL filings (CIK 0001178670). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.

↑ ↓ to move · ↵ to open